PharmaJet creates two SABs

PharmaJet Logo

Closely-held PharmaJet created two scientific advisory boards (SABs) – infectious diseases and oncology – comprised of leading pharmaceutical industry experts in immunology, cancer, research, and policy shaping.

“The formation of our SABs is a significant step forward in our mission to demonstrate how our delivery technology can improve the performance of vaccines and therapeutics,” Chris Cappello, PharmaJet’s President and CEO, said in a statement.

The new SABs include:

Infectious Diseases

  • Cornelia Dekker, M.D., Professor of Pediatrics (Infectious Diseases), Emerita, Stanford University School of Medicine; former Vice President, Clinical Research and Medical Affairs, Chiron Vaccines
  • James Merson, Ph.D., Chief Virology Officer, stealth Oncology company; former SVP and CSO, Vaccine Immunotherapeutics Research Unit, Pfizer
  • Jonathan Nguyen-Van-Tam, independent consultant, former Medical Di-rector Sanofi Pasteur MSD and Former Deputy Chief Medical Officer, UK Government
  • Bali Pulendran, Ph.D., Co-Director, Institute for Immunity, Transplantation and Infection, Stanford University, and Violetta L. Horton Professor of Pathology, and of Microbiology and Immunology
  • Brian Ward, MDCM, Professor of Infectious Diseases/Microbiology, McGill University; former Medical Officer, Medicago Inc.


  • Michael Gibson, M.D., Ph.D., FACP, Director, Translational Research for Esophago-Gastric Cancer (EGC) at the Vanderbilt-Ingram Cancer Center (VICC)
  • Stephanie Mazzei, MSc, Founder and Director, OncoLogic Inc.; global oncology Strategic Advisor
  • Douglas McNeel, M.D., Ph.D., Professor of Medicine, Director, Solid Tumor Immunology Research, Co-Director, University of Wisconsin Prostate SPORE, UW Carbone Cancer Center
  • James Merson, Ph.D., see above.
  • Patrick Ott, M.D., Ph.D., Clinical Director, Melanoma Center, Dana Far-ber Cancer Institute